The anticancer drugs / William B. Pratt [and three others].
Material type:
- 9780195067385
- RC 271.C5 .P73 1994

Item type | Current library | Home library | Collection | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|---|
![]() |
National University - Manila | LRC - Main General Circulation | Pharmacy | GC RC 271.C5 .P73 1994 (Browse shelf(Opens below)) | c.1 | Available | NULIB000004117 |
Includes bibliographical references and index.
Principles of cancer chemotherapy -- Cancer problem -- Some milestones in the development of cancer chemotherapy -- Determinants of drug responsivveness -- Resistance to anticancer drugs -- Anticancer drugs -- Antimetabolites -- Folate antagonists, pyrimidine antagonists, purine antagonists, sugar-modified analogs, ribonucleotide reductase inhibitors -- Covalent DNA binding drugs -- Nitrogen mustards, aziridines, alkane sulfonates, nitrosoureas, platinum compounds, monoalkylating agents -- Noncovalent DNA binding drugs -- Antrhacyclines, mitoxantrone, dactinomycin, bleomycin, plicamycin -- Inhibitors of chromatin function -- Topoisomerase inhibitors, microtubule inhibitors -- Drugs affecting endocrine function -- Glucocorticoids, estrogens, antiestrogens, progestins, androgens, antiandrogens, LHRH (GnRH) agonists, aromatase inhibitors, adrenocortical suppressors -- Clinical cancer chemotherapy -- Choice of drugs for cancer chemotherapy -- Cancer treatment. (cont) New directions in cancer chemotherapy -- Anticancer drug development -- Biological treatments of cancer -- Potential targets for new anticancer drugs.
This is an up-to-date review of the pharmacology, mechanisms of action, development of resistance, and toxicity of cancer chemotherapeutic agents. A rationale for their clinical use, based on cancer cell biology, is given for each class of drugs.
There are no comments on this title.